Skip to main content

Table 1 Eligible trials with their inclusion criteria and magnesium regimens as at September 2011

From: Antenatal magnesium individual participant data international collaboration: assessing the benefits for babies using the best level of evidence (AMICABLE)

Trial GA at entry (weeks) Treatment intent Magnesium sulphate regimen Comparator
Mittendorf 2002[39] 25 to 33 Tocolysis (cervical dilatation < 4 cm) or; 4 g bolus followed by 2 to 3 g/hour maintenance Alternative tocolytic
   Neuroprotection of the fetus/infant/child (dilatation ≥ 4 cm) 4 g bolus (no repeats) Placebo
Rouse 2008[40] 24 to 32 Neuroprotection of the fetus/infant/child 6 g over 20-30 mins followed by 2 g/hr (retreatment permitted) Placebo
Crowther 2003[41] less than 30 Neuroprotection of the fetus/infant/child 4 g over 20 mins, then 1 g/hour for up to 24 hours or birth (no repeats) Placebo
Marret 2008[42] less than 33 Neuroprotection of the fetus/infant/child 4 g (no repeats) Placebo
The Magpie Trial Collaborative Group 2002[43] less than 37 Neuroprotection of the pre-eclamptic mother 4 g over 10-15 mins, then either 1 g/hour for 24 hours, or 5 g every 4 hours IM for 24 hours (no repeats) Placebo